
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
Jun 26, 2025 01:48 am UTC| Business Health Science
Shares of Neuren Pharmaceuticals Ltd (ASX:NEU) jumped over 10% on Thursday after the company announced a key development in its rare disease pipeline. The U.S. Patent and Trademark Office has approved Neurens patent...

CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation
Jun 25, 2025 02:03 am UTC| Politics Health Science
A presentation on thimerosal, a mercury-based vaccine preservative, set to be delivered to the CDCs advisory committee has come under scrutiny for referencing a non-existent study. The report, Thimerosal as a Vaccine...

US Launches Major Campaign to Promote Health Wearables
Jun 25, 2025 01:20 am UTC| Politics Health
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced plans for a nationwide advertising campaign encouraging Americans to adopt health wearables, such as heart rate and continuous glucose monitors. The...

Muscle-Preserving Obesity Drug Market Projected to Surpass $30B by 2035
Jun 21, 2025 02:02 am UTC| Business Health
The race to develop muscle-preserving treatments alongside popular obesity drugs like Eli Lillys (NYSE:LLY) Zepbound and Novo Nordisks (NYSE:NVO) Wegovy is gaining momentum, with analysts at TD Cowen forecasting sales...

Australia’s TGA Sues News Corp, Mamamia Over Medicinal Cannabis Ads
Jun 20, 2025 04:17 am UTC| Business Law Health
Australias health regulator, the Therapeutic Goods Administration (TGA), has launched legal action against News Corp Australia-owned News Life Media, Mamamia.com.au, AG Therapeutics, and public relations firm Straight Up...

Kennedy's Vaccine Panel Overhaul Sparks Expert Backlash and Safety Concerns
Jun 17, 2025 01:56 am UTC| Politics Health Governance
U.S. Health Secretary Robert F. Kennedy Jr.s recent dismissal of all 17 members of the CDCs Advisory Committee on Immunization Practices (ACIP) has triggered a strong backlash from vaccine experts. The ousted panelists...

Roche Halts Elevidys Dosing in Some Duchenne Patients After Fatalities
Jun 16, 2025 09:21 am UTC| Business Health
Roche (SIX:ROG) shares dropped 2% on Monday after the company paused dosing of its gene therapy Elevidys in non-ambulatory patients with Duchenne muscular dystrophy following two deaths caused by acute liver failure. In a...